BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 12, 2025
Home » Blogs » BioWorld MedTech Perspectives » Augmented reality check

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Augmented reality check

Aug. 16, 2017
By Omar Ford

OpenSight Press 1

My first real exposure to what's commonly called augmented reality was about a year ago when one of my former colleagues introduced me to Pokemon Go. I remember her telling me that you could actually hold up your smartphone or tablet and see actual Pokemon along the street.

Now fast forward by a year, and most of the hype surrounding the game has waned off. However there is still tremendous enthusiasm with augmented reality. In fact reality altering technology isn't just regulated to Pokemon and the video gaming industry, it has invaded health care and looks to be more than a fad.

Recently, I had the pleasure of interviewing Neuroradiologist Wendell Gibby, who has found a way to insert augmented reality into an automated percutaneous lumbar discectomy (APLD) procedure for disk herniation. Gibby founded in Novarad Corp. which has developed the Opensight software to be used in conjunction with Microsoft Corp.'s Hololens technology.

When I talked to him you could just hear the excitement in his voice. This veteran Neuroradiologist was literally blown away by what Opensight and the Hololens could do.

In the APLD procedure, an image of the patient's spine was taken with CT, then loaded onto the Opensight software. From there the image was transferred through the cloud to the Hololens, which was worn by Gibby. That image was then projected onto the patient's body while Gibby did the procedure.

Just imagine the impact this could have on other procedures once it becomes tested and perfected, Gibby said. He kept repeating, the ability to look at the inside of the body on the surface of the patient is incredible!

"I could never have imagined this in my wildest dreams," Gibby said.

Augmented reality is quickly taking root into the health care space, offering enhanced imaging and easier surgical procedures. During the 2016 Cleveland Clinic Medical Innovation summit, augmented reality for surgery made the top 10 list for medical innovations.

This innovation, which emerged from the same technology that fueled the gaming industry, offers surgeons – especially those conducting neurosurgery and retinal microsurgery – the opportunity to better identify tissue structures, said Rishi Singh, of the Clinic's Cole Eye Institute, who noted that his experience with the technique "felt ergonomically better."

Augmented reality can be a useful tool in health care. I don't think this is a fad, but rather the start of something big. But most importantly it's getting physicians and surgeons to dream again.

 

 

 

 

 

 

 

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 11, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Brain and encephalography

    DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

    BioWorld
    Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
  • Illustration of head with maze that is missing parts

    CTAD 2025: The challenges of combination therapies for dementia

    BioWorld Science
    At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing